Filspari

sparsentan

Approval

ApplicationNDA 216403
Approval dateFeb 17, 2023
Approval year2023
SponsorTravere

FDA-approved use

To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Filspari: